-

Bayer Corn Trait Gains EPA Approval: VT4PRO™ with RNAi Technology to Launch in US as Early as 2024

Versatile product will provide broad geographic fit and the widest spectrum of insect defense from Bayer

ST. LOUIS--(BUSINESS WIRE)--Bayer announced today the commercial registrations from the EPA for the traits that will enable the commercialization of its newest corn product, VT4PRO™ with RNAi Technology, in the United States. VT4PRO™ Technology* will provide US farmers an additional option within the already-strong Bayer corn product portfolio to help control troublesome above-ground and below ground pests.

VT4PRO™ Technology will mark the first product that combines the power of the three modes of built-in action in Trecepta® Technology, an elite above-ground pest package for corn that controls insects such as corn earworm and western bean cutworm, along with an RNAi-based mode of action, the latest defense to help manage corn rootworm.

“We’re excited about the potential of this product and believe it will provide tremendous value for farmers, helping provide added protection against some of the toughest corn pests,” said Scott Stein, North America Corn Product Management Lead. “The addition of VT4PRO™ Technology to our portfolio gives farmers another choice in Bayer’s already-robust product lineup. We anticipate that this offering will have a broad geographic fit and will provide corn growers the widest spectrum of insect defense from Bayer.”

A complement to Bayer’s existing portfolio, VT4PRO™ Technology will complement other products like SmartStax® PRO Technology and offer an additional option for growers looking for products that will perform well in low-to-moderate corn rootworm pressure conditions, along with potential higher risk for corn earworm or western bean cutworm.

“This product is another example of Bayer’s commitment to developing and delivering innovative products for farmers through our corn product pipeline,” said Stein. “With an annual investment of more than $2 billon, we’re dedicated to developing technology that provides innovative solutions that help growers address the tough challenges they face on their farms.”

Bayer plans to conduct large scale field testing of VT4PRO™ Technology during the 2022 and 2023 growing seasons with the potential to launch commercial volumes as early as 2024, pending state registrations.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

*VT4PRO™ with RNAi Technology is not currently available for commercially sale or planting. ALWAYS READ AND FOLLOW IRM, WHERE APPLICABLE, GRAIN MARKETING AND ALL OTHER STEWARDSHIP PRACTICES AND PESTICIDE LABEL DIRECTIONS. ©2022 Bayer Group. All rights reserved.

Contacts

Bayer - Brian Leake 314.370.3285
Brian.Leake@Bayer.com

Bayer


Release Versions

Contacts

Bayer - Brian Leake 314.370.3285
Brian.Leake@Bayer.com

More News From Bayer

One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin

WHIPPANY, N.J.--(BUSINESS WIRE)--One A Day®, the multivitamin and supplement brand from Bayer, today announced a new formula for One A Day® Women's Multi Gummy, which now delivers 1,000 mcg of Biotin per serving (serving size is two gummies). The new formulation contains more biotin† with 2833% Daily Value (DV) than other leading multivitamin gummies including Olly Women’s Multi, Nature Made Women's Advanced Multivitamin Gummies, and Vitafusion Women's Multi (1000 mcg vs 150 mcg), while continu...

New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters

LEVERKUSEN, Germany--(BUSINESS WIRE)--Self-care, when effectively integrated into health systems, can improve health outcomes, expand access to healthcare services and reduce pressure on overstretched health systems, according to new research by Economist Enterprise. The research, supported by Bayer and published in a report titled “Making self-care work: integrating self-care into health systems”, cites existing evidence estimating that self-care practices can deliver approximately US$ 179 bil...

Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials

DETROIT--(BUSINESS WIRE)--Bayer, a global life sciences company, and Henry Ford Health today announced a strategic partnership to expand clinical trial opportunities for patients. The work brings together Bayer’s global drug development expertise with Henry Ford Health’s comprehensive clinical research program and its deep connection to the communities it serves. “Clinical trials are often the first opportunity patients have to access cutting-edge treatments,” said Dr. David Lanfear, Chief Scie...
Back to Newsroom